UBS on Swiss equities: Selloff creates an opportunity to reposition

UBS upgraded Swiss equities to "Attractive" after the SMI fell close to 15% intra-month, arguing the pullback presents a constructive entry point; the SMI trades around 16x forward earnings (long-term avg 15.8x) with a ~3.2% dividend yield. UBS also upgraded European health care to Attractive (yield ~2.7%), recommends shifting from cyclical exposure into quality, profitability leaders and dividend growers, and expects currency drag to ease from Q2; Brent crude is trading near $113/bbl.

Analysis

A tactical reweight into high-quality Swiss names makes sense only if the current geopolitical premium to risk persists while growth stays sluggish; key second-order beneficiaries will be companies with predictable cash returns and low marginal energy intensity because they compound distributions when cyclicals de-rate. Conversely, Swiss firms with material domestic energy or logistics input shares — and suppliers into discretionary export chains — will see margin pressure faster than headline demand metrics imply, creating an asymmetric opportunity to short or hedge those exposures.

Primary catalysts to watch are the trajectory of the regional security shock and its transmission into energy and FX markets over the next 1–3 quarters; a renewed flare-up would lengthen the risk premium and deepen outperformance for defensive cash generators, while any rapid diplomatic thaw or coordinated supply response would compress oil and lift cyclical recovery plays within 30–90 days. Central bank reactions and FX flows are a medium-term backstop: a marked CHF re-appreciation would reintroduce reporting risk for exporters even if operations improve, and SNB policy surprises could reprice dividend-supporting yields within months.

The consensus trade — rotate into Swiss dividends — is directionally sensible but underestimates dispersion. The market is pricing a uniform reward for “defensive” labels; we should discriminate by balance-sheet optionality, CAPEX cyclicality, and energy pass-through ability. That argues for concentrated longs in high-margin, low-capex compounders, funded by targeted shorts or puts on energy-sensitive industrials and travel-exposed mid/small caps, with explicit FX and oil hedges to convert a passive income tilt into convex, event-driven payoff profiles.

Key Decisions for Investors

• Pair trade (3–9 months): Long EWL (iShares MSCI Switzerland ETF) 60% weight / Short EWG (iShares Germany ETF) 40% weight — target +12–18% if Swiss defensive outperformance continues; stop-loss at -8% absolute on EWL leg. Rationale: capture relative rerating and dividend stability while hedging a Europe-wide risk-off move.
• Long selective pharma/dividend compounders (12 months): Buy NVS (Novartis) and RHHBY (Roche ADR) equal-weight — target total return 15–25% from earnings leverage and buybacks/dividend stability; hedge 30–40% with out-of-the-money puts (6–9 month) to cap downside to ~10% in a severe risk-off.
• Event/hard-landing hedge (3–6 months): Buy ABB (ABB) 3–6 month put options or 1–2% notional CDS-synthetic if available — protects portfolio from energy-driven capex cliff in industrials; cost is insurance premium, acceptable if it limits tail loss to <12% on aggregated cyclicals exposure.
• Special situation (2–6 months): Accumulate UBS (UBS) stock on pullbacks below short-term resistance as a sentiment trade — allocate up to 2% portfolio, target +20% re-rating if bank-sector risk premia compress; use a 10% stop-loss and cap position size given geopolitical volatility.